In a previous study, we reported a novel 14-membered ring macrolide, migrastatin isolated from culture broth of Streptomyces sp. MK929-43F1 as an inhibitor of tumor cell migration1). Recently, however, we found that our original migrastatin isolate contained teleocidin-related compounds which display strong inhibitory activity against tumor cell migration. In this report, we describe the effects of teleocidin-free migrastatin on tumor cell migration and on the growth of several types of tumor cells. Whenthe original migrastatin sample was subjected to HPLC (Capcell Pak C18 column, 20X250mm) developing with 70% aq acetonitrile, a potent migration inhibitory activity was eluted in a fraction other than migrastatin, indicating that the migration inhibitory activity of our original migrastatin samples reported previously was due to the activity of an impurity. The potent migration inhibitory fraction contained teleocidin-related compounds, as judged from UV spectrum. Teleocidin-related compounds are knownto inhibit [3H]PDBu binding to the cell surface2), therefore, we clarified the content of teleocidin-related compoundsin the original migrastatin sample as evaluated by [3H]PDBu binding assay (Fig. 1) migrastatin reported previously4), possibly due to the low content of impurities. Migration inhibitory activities of pure migrastatin and pendolmycin were assayed by the wound healing method as described before1^In brief, a standardized scratch was madethrough a con fluent monolayer of humanesophageal carcinoma EC17cells, and then the cells from the cut edge were allowed to migrate for 24 hours5). Pendolmycin as well as teleocidin B inhibited migration of EC17 cells at lOng/ml (data not shown). On the other hand, EC17 cells migrated inwardly and covered a great area of the scratch even in the presence of 100 /ig/ml of migrastatin. However, when the EC17 cells were pretreated with migrastatin 
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for 24 hours before scratching, lO^g/ml of migrastatin significantly inhibited the migration of EC17 cells, and 30 /ig/ml of migrastatin completely inhibited cell migration as judged from the residual area between the inwardly migrating EC17 cells from the edges of the scratch (Fig. 2) . Migrastatin inhibited migration of EC17 cells with an IC50 value of about 10^g/ml, but it inhibited cell proliferation of EC17 cells with an IC50 value of 82/ig/ml (Table 1) , and it failed to induce cell death in EC17 cells up to 100/xg/ml. These results indicated that inhibition of migration of EC 1 7 cells by migrastatin should not be due to the inhibition of cell proliferation or induction cell death by the drug. One ng/ml of pendolmycin did not inhibit migration even with 24 hours pretreatment.
Additionally, erythromycin and clarithromycin, other 14-membered ring macrolides, did not inhibit migration ofEC17 cells up to lOO^ag/ml. Next we examined the effect of migrastatin on cell proliferation. Various types of cultured cells were treated with migrastatin, and after 72 hours, their cell numbers were determined by MTTassay. As shown in Table 1 malignancy in tumor cells. Therefore, we next examined the effect of migrastatin on the growth ability of human small cell lung carcinoma Ms-1 cells under anchorageindependent conditions, and compared it to that under anchorage-dependent conditions. Ms-1 cells were seeded on plastic dishes or antiadhesive polymer (Poly-HEMA)6) coated dishes in the presence of various concentrations of migrastatin, respectively, and after 4 days, the cell numbers were measured by MTTassay. Under anchorage-dependent conditions, migrastatin did not significantly reduce the growth rate up to 30^g/ml (Fig. 3a) , and 100jug/ml of migrastatin induced cell death as evaluated by trypan blue dye exclusion assay (Fig. 3b) . In addition, this cell death was inhibited by the overexpression of anti-apoptic protein, Bcl-2 or Bcl-XL in Ms-1 cells (Fig. 3b) . On the other hand, migrastatin (l~100 /ig/ml) inhibited the cell growth of Ms-1 cells under anchorage-independent conditions in a dosedependent manner (Fig. 3a) . Thus, migrastatin reduced the anchorage-independent growth ability of Ms-1 cells. The growth rate of Ms-1 cells under anchorage-independent condition was lower than that under anchorage-dependent condition (data not shown). However, because many anticancer drugs tested such as adriamycin, vinblastine or camptothecin showed similar inhibitory effects in two culture conditions (data not shown), selective growth inhibitory effect of migrastatin seen in anchorageindependent conditions should not be due to this different growth rate in two conditions. Integrin-signaling is thought to be involved in both cell migration7) and anchorageindependent growth8), therefore, effect of migrastatin on integrin-signaling should be studied.
